A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2013-11-25
Target enrollment:
Participant gender:
Summary
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced
multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose
dexamethasone or high-dose dexamethasone alone in studies Thal-MM-003, CC-5013-MM-009 and
CC-5013-MM-010 due to the development of documented disease progression or the inability to
tolerate the lowest dosing regimen per previous protocol of thalidomide and/or high-dose
dexamethasone without grade 3 or 4 toxicity.